Business
GroSciences Initiates Beta-testing of Tru-Hemp ID In North Carolina and Vermont
GroSciences Initiates Beta-testing of Tru-Hemp ID In North Carolina and Vermont.
About this update from Hypha Labs, Inc.
[{"type":"text","content":"\n Tru-Hemp ID Can Effectively Distinguish Between Hemp and Cannabis BOULDER, CO, Aug. 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Digipath, Inc. (OTCQB: DIGP), a leading independent testing laboratory, data analytics and formulation firm focused on the developing cannabis and hemp markets, is pleased to announce that GroSciences, its wholly owned subsidiary, has successfully completed beta-testing of its “Tru-Hemp ID” kit. Tru-Hemp ID distinguishes hemp cultivars from drug-type I cannabis (which are different genetic cultivars of cannabis) via a DNA test of the plant sample. Under the 2018 Farm Bill that legalized hemp cultivation, hemp is defined as having less than 0.3% delta-9-THC by dry weight.  As a result, compliance with the 2018 Farm Bill is usually determined by analyzing the THC content of a particular plant sample.  Tru-Hemp ID offers a simpler method for determining the strain of a particular plant in the form of a genetic test.  A full analysis of all data collected thus far using the Tru-Hemp ID kit that correlates the genetic outcome of samples with their actual THC content will be forthcoming. “Hemp farmers in North Carolina and Vermont were very receptive to using the Tru-Hemp ID kit,” stated Cindy S. Orser, PhD, Chief Science Officer, Digipath, Inc.  “Farmers want to have the ability to definitively verify what they are buying, particularly when purchasing hemp seeds from other states or countries, or cannabis clones.” Dr. Orser also spent time with the Vermont Department of Agricultural staff, including the Vermont hemp program director, Cary Giguere.  Vermont, a progressive cannabis state, already provides for the use of genetic testing to discriminate hemp cultivars from drug-type I cannabis in lieu of a chemical analysis of the mature flower for delta-9-THC content under the 2018 Farm Bill. “It is rewarding to see our first genetic product entering a successful beta test phase,” added Dr. Orser. “We are enthusiastic about the market opportunity and the interest from hemp farmers and hemp regulators.” About Digipath, Inc. (OTCQB: DIGP) Digipath, Inc., supports the cannabis industry’s best practices for reliable testing, data acquisition, formulations, and new canna-tech to the cannabis industry. Digipath Labs pro...